Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Functional and genomic characterization of a xenograft model system for the study of metastasis in triple-negative breast cancer.

Johnstone CN, Pattison AD, Gorringe KL, Harrison PF, Powell DR, Lock P, Baloyan D, Ernst M, Stewart AG, Beilharz TH, Anderson RL.

Dis Model Mech. 2018 May 10. pii: dmm.032250. doi: 10.1242/dmm.032250. [Epub ahead of print]

2.

Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.

Johnson J, Bessette DC, Saunus JM, Smart CE, Song S, Johnston RL, Cocciardi S, Rozali EN, Johnstone CN, Vargas AC, Kazakoff SH, BioBank VC, Khanna KK, Lakhani SR, Chenevix-Trench G, Simpson PT, Nones K, Waddell N, Al-Ejeh F.

Breast Cancer Res Treat. 2018 Feb 21. doi: 10.1007/s10549-018-4719-9. [Epub ahead of print]

PMID:
29468485
3.

Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential.

Fietz ER, Keenan CR, López-Campos G, Tu Y, Johnstone CN, Harris T, Stewart AG.

Sci Rep. 2017 Mar 6;7:43774. doi: 10.1038/srep43774.

4.

Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes.

Tu Y, Johnstone CN, Stewart AG.

Pharmacol Res. 2017 May;119:278-288. doi: 10.1016/j.phrs.2017.02.011. Epub 2017 Feb 14. Review.

PMID:
28212890
5.

Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer.

Johnstone CN, Chand A, Putoczki TL, Ernst M.

Cytokine Growth Factor Rev. 2015 Oct;26(5):489-98. doi: 10.1016/j.cytogfr.2015.07.015. Epub 2015 Jul 14. Review.

6.

Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease.

Williams BB, Tebbutt NC, Buchert M, Putoczki TL, Doggett K, Bao S, Johnstone CN, Masson F, Hollande F, Burgess AW, Scott AM, Ernst M, Heath JK.

Dis Model Mech. 2015 Aug 1;8(8):805-15. doi: 10.1242/dmm.019935. Epub 2015 May 8.

7.

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.

Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RS, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL, Restall CM, Lucas E, Pearson HB, Deb S, Britt KL, Rizzitelli A, Li J, Harmey JH, Pouliot N, Anderson RL.

Dis Model Mech. 2015 Mar;8(3):237-51. doi: 10.1242/dmm.017830. Epub 2015 Jan 29.

8.

BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity.

Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL, Anderson RL.

Cancer Res. 2014 Sep 15;74(18):5091-102. doi: 10.1158/0008-5472.CAN-13-3171.

9.

Resolvin D2 supports MCF-7 cell proliferation via activation of estrogen receptor.

Al-Zaubai N, Johnstone CN, Leong MM, Li J, Rizzacasa M, Stewart AG.

J Pharmacol Exp Ther. 2014 Oct;351(1):172-80. doi: 10.1124/jpet.114.214403. Epub 2014 Jul 30.

10.

MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.

Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ, Gregory PA, Khew-Goodall Y.

Oncogene. 2014 Jul 31;33(31):4077-88. doi: 10.1038/onc.2013.370. Epub 2013 Sep 16.

PMID:
24037528
11.

LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms.

King CE, Wang L, Winograd R, Madison BB, Mongroo PS, Johnstone CN, Rustgi AK.

Oncogene. 2011 Oct 6;30(40):4185-93. doi: 10.1038/onc.2011.131. Epub 2011 May 30.

12.

Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.

Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD.

PLoS One. 2011 Apr 13;6(4):e18064. doi: 10.1371/journal.pone.0018064.

13.

IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2.

Mongroo PS, Noubissi FK, Cuatrecasas M, Kalabis J, King CE, Johnstone CN, Bowser MJ, Castells A, Spiegelman VS, Rustgi AK.

Cancer Res. 2011 Mar 15;71(6):2172-82. doi: 10.1158/0008-5472.CAN-10-3295. Epub 2011 Jan 20.

14.

Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2.

Khau T, Langenbach SY, Schuliga M, Harris T, Johnstone CN, Anderson RL, Stewart AG.

FASEB J. 2011 Feb;25(2):483-96. doi: 10.1096/fj.09-154096. Epub 2010 Oct 7.

PMID:
20930115
15.

DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status.

Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, Simpson P, da Silva L; kConFab Investigators, Khanna K, Lakhani S, Boshoff C, Chenevix-Trench G.

Am J Hum Genet. 2010 Mar 12;86(3):420-33. doi: 10.1016/j.ajhg.2010.02.008. Epub 2010 Mar 4.

16.

Subtypes of familial breast tumours revealed by expression and copy number profiling.

Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, Godwin AK, Hogervorst FB, Couch F; kConFab Investigators, Grimmond S, Flanagan JM, Khanna K, Simpson PT, Lakhani SR, Chenevix-Trench G.

Breast Cancer Res Treat. 2010 Oct;123(3):661-77. doi: 10.1007/s10549-009-0653-1. Epub 2009 Dec 4.

PMID:
19960244
17.

Low frequency of MLL3 mutations in colorectal carcinoma.

Vakoc CR, Wen YY, Gibbs RA, Johnstone CN, Rustgi AK, Blobel GA.

Cancer Genet Cytogenet. 2009 Mar;189(2):140-1. doi: 10.1016/j.cancergencyto.2008.10.014. No abstract available. Erratum in: Cancer Genet Cytogenet. 2009 Jun;191(2):115.

18.

MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.

Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Bützow R, Croce CM, Coukos G, Zhang L.

Cancer Res. 2008 Dec 15;68(24):10307-14. doi: 10.1158/0008-5472.CAN-08-1954.

19.

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.

Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Bützow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9. doi: 10.1073/pnas.0801615105. Epub 2008 May 5.

20.

Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation.

Johnstone CN, Mongroo PS, Rich AS, Schupp M, Bowser MJ, Delemos AS, Tobias JW, Liu Y, Hannigan GE, Rustgi AK.

Mol Cell Biol. 2008 Jan;28(2):687-704. Epub 2007 Nov 12.

21.

The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.

Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK.

Genes Dev. 2007 Nov 1;21(21):2788-803.

22.

IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms.

Takaoka M, Kim SH, Okawa T, Michaylira CZ, Stairs DB, Johnstone CN, Andl CD, Rhoades B, Lee JJ, Klein-Szanto AJ, El-Deiry WS, Nakagawa H.

Cancer Biol Ther. 2007 Apr;6(4):534-40.

23.

TGF-betaRII rescues development of small intestinal epithelial cells in Elf3-deficient mice.

Flentjar N, Chu PY, Ng AY, Johnstone CN, Heath JK, Ernst M, Hertzog PJ, Pritchard MA.

Gastroenterology. 2007 Apr;132(4):1410-9. Epub 2007 Feb 25.

PMID:
17408644
24.

N-cadherin and keratinocyte growth factor receptor mediate the functional interplay between Ki-RASG12V and p53V143A in promoting pancreatic cell migration, invasion, and tissue architecture disruption.

Deramaudt TB, Takaoka M, Upadhyay R, Bowser MJ, Porter J, Lee A, Rhoades B, Johnstone CN, Weissleder R, Hingorani SR, Mahmood U, Rustgi AK.

Mol Cell Biol. 2006 Jun;26(11):4185-200.

25.

PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas.

Johnstone CN, Castellví-Bel S, Chang LM, Sung RK, Bowser MJ, Piqué JM, Castells A, Rustgi AK.

Genomics. 2005 Mar;85(3):338-51.

PMID:
15718101
26.

Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer.

Mongroo PS, Johnstone CN, Naruszewicz I, Leung-Hagesteijn C, Sung RK, Carnio L, Rustgi AK, Hannigan GE.

Oncogene. 2004 Nov 25;23(55):8959-70.

PMID:
15467740
27.

Ha-Ras(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction.

Takaoka M, Harada H, Deramaudt TB, Oyama K, Andl CD, Johnstone CN, Rhoades B, Enders GH, Opitz OG, Nakagawa H.

Oncogene. 2004 Sep 2;23(40):6760-8.

PMID:
15273725
28.

ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers.

Johnstone CN, Castellví-Bel S, Chang LM, Bessa X, Nakagawa H, Harada H, Sung RK, Piqué JM, Castells A, Rustgi AK.

Gene. 2004 Jul 7;336(1):59-71.

PMID:
15225876
29.

Evaluation of PARVG located on 22q13 as a candidate tumor suppressor gene for colorectal and breast cancer.

Castellví-Bel S, Castells A, Johnstone CN, Piñol V, Pellisé M, Elizalde JI, Romo N, Rustgi AK, Piqué JM.

Cancer Genet Cytogenet. 2003 Jul 1;144(1):80-2.

PMID:
12810262
30.

AACR special meeting in cancer research: colon cancer--genetics to prevention.

Johnstone CN, Chang LM, Ernst M; American Association for Cancer Research.

Cancer Res. 2002 Nov 15;62(22):6779-83. No abstract available.

31.

Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression.

Johnstone CN, White SJ, Tebbutt NC, Clay FJ, Ernst M, Biggs WH, Viars CS, Czekay S, Arden KC, Heath JK.

J Biol Chem. 2002 Sep 13;277(37):34531-9. Epub 2002 Jul 11.

32.
33.

Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells.

Johnstone CN, Tebbutt NC, Abud HE, White SJ, Stenvers KL, Hall NE, Cody SH, Whitehead RH, Catimel B, Nice EC, Burgess AW, Heath JK.

Am J Physiol Gastrointest Liver Physiol. 2000 Sep;279(3):G500-10.

34.

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily.

Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW.

Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):469-74.

Supplemental Content

Loading ...
Support Center